Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649556 | 0.85 | ALDH1A1 (0.50) | ABCB1ABCG2 | |
| SCHEMBL26015871 | 0.85 | ALDH1A1 (0.50) | ABCB1ABCG2 | |
| SCHEMBL1621417 | 0.79 | FGFR1 (0.33) | SMN1; SMN2ABCB1HTT | |
| SCHEMBL1620763 | 0.78 | ERN1 (0.36) | LMNA | |
| SCHEMBL5781161 | 0.78 | ENPP2 (0.34) | SMN1; SMN2ABCB1LMNAHTT | |
| SCHEMBL1314001 | 0.76 | AGXT (0.42) | SMN1; SMN2LMNAHTT | |
| SCHEMBL501339 | 0.76 | TACR1 (0.32) | SMN1; SMN2LMNAHTT | |
| SCHEMBL5782201 | 0.76 | ABCB1 (0.43) | SMN1; SMN2ABCB1 | |
| SCHEMBL4038060 | 0.76 | PDE4B (0.35) | SMN1; SMN2ABCB1 | |
| SCHEMBL26978213 | 0.76 | FFAR1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194046-B1 | Triazolone derivative | EISAI R&D MAN CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
| US-7928228-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2010-07-29 | — | — | US | disclosed |
| EP-2194046-A1 | Triazolone derivative | Eisai R&D Management Co., Ltd. (JP) | 2010-06-09 | — | — | EP | disclosed |
| EP-2000465-A1 | TRIAZOLONE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-12-10 | — | — | EP | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | H1-0, H1-10, H1-2 | SMN1; SMN2 3953/4885ALKBH1 3350/4885DRD4 85/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | SMN1; SMN2 4234/4885ALKBH1 3410/4885DRD4 117/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | SMN1; SMN2 3935/4885ALKBH1 4063/4885DRD4 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.